Bino Pathiparampil, Head of Research at Elara Securities, says HUL’s recovery depends on the execution of its strategy to tap new-age consumption trends as traditional FMCG growth remains muted. He sees near-term rebound potential in IT stocks after sharp corrections, though AI-led growth may take time to emerge. He adds semaglutide could create a $1 billion opportunity in India’s pharma market over the next four years.
